Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Brand Name :
Xywav
Synonyms :
Class :
Sedative and hypnotic
Dosage Forms & Strengths
Oral solution-500mg/ml (calcium oxybate-234mg/ml, magnesium oxybate 96mg/ml, potassium oxybate-13mg/ml, and sodium oxybate-4mg/ml)
4.5
g
Tablet
Orally
Once a day in the night
divided into two doses- 2.25g half strength and 2.25g taken 2.5-4
hours
later
increase up to 1.5g/night at weekly intervals
Twice-nightly regimen:
Initial dose: ≤4.5 g orally in two doses
Maximum dose: ≤9g orally in two doses
Once-nightly regimen:
Initial dose: ≤3 g orally half strength
Maximum dose:6 g orally half strength
Dosage Forms & Strengths
Oral solution-500mg/ml (calcium oxybate-234mg/ml, magnesium oxybate 96mg/ml, potassium oxybate-13mg/ml, and sodium oxybate-4mg/ml)
<7 years: Safety and efficacy not established
≥7 years
<20 kgs: Start with the lower dose
20 to <30kgs:
Initial dose-2g orally/day, divided into two doses
Maintenance dose- increase by 1g orally/night
Maximum dose-6g/day
30 to <45kgs:
Initial dose-3g orally/day, divided into two doses
Maintenance dose-increase by 1g orally/night
Maximum dose- 7.5g/day
>45 kgs:
Initial dose- 4.5g orally/day, divided into two doses
Maintenance dose-increase by 1.5g orally/night
Maximum dose-9g/day
<7 years: Safety and efficacy not established
≥7 years
<20 kgs: Start with the lower dose
20 to <30kgs:
Initial dose-2g orally/day, divided into two doses
Maintenance dose- increase by 1g orally/night
Maximum dose-6g/day
30 to <45kgs:
Initial dose-3g orally/day, divided into two doses
Maintenance dose-increase by 1g orally/night
Maximum dose-7.5g/day
>45 kgs:
Initial dose-4.5g orally/day, divided into two doses
Maintenance dose-increase by 1.5g orally/night
Maximum dose-9g/day
Refer adult dosing
may have an increased CNS depressant effect when combined with oxybate salt products
may have an increased CNS depressant effect when combined with oxybate salt products
may have an increased CNS depressant effect when combined with oxybate salt products
may have an increased CNS depressant effect when combined with oxybate salt products
may have an increased CNS depressant effect when combined with oxybate salt products
may enhance the serum concentration
may increase the CNS depressant effect of CNS Depressants
by the way of pharmacodynamic synergism, the effects of sedation can be raised when butabarbital is combined with sodium/potassiu/magnesium/calcium oxybates
The effect of either of the drugs is increased due to pharmacodynamic synergism. May result in respiratory depression, coma, or death
may diminish the calcium salts excretion
may diminish the calcium salts excretion
may diminish the calcium salts excretion
may diminish the calcium salts excretion
may be increased risk of adverse effects such as respiratory distress, sedation, coma or death
An enhancement in activity of either of the drugs occurs due to pharmacodynamic synergistic effect when magnesium, potassium, calcium/sodium oxybates is taken with papaverine
Frequency defined:
Narcolepsy
>10%
Adults
Nausea
Headache
Pediatrics
Headache
Nausea
Vomiting
Enuresis
1-10%
Adults
Anxiety
Dry mouth
Enuresis
Dizziness
Irritability
Tremor
Muscle spasm
Paresthesia
Parasomnia
Pediatrics
Dizziness
Decreased appetite
Idiopathic hypersomnia
>10%
Anxiety
Nausea
Headache
1-10%
Balance disorder
Bruxism
Confusional state
Dry mouth
Fatigue
Fall
Muscle spasm
Snoring
Parasomnia
Tremor
Pregnancy consideration: N/A
Lactation: Insufficient data available
Pregnancy category:
Patient information leaflet
Generic Name: Calcium, magnesium, potassium, and sodium oxybates
Pronounced: [ KAL-see-um, mag-NEE-zee-um, Poe-TAS-ee-um, and-SOE-dee-um-OX-i-bate]
Why do we use Calcium, magnesium, potassium, and sodium oxybates?
It is used to treat cataplexy or to reduce daytime sleepiness caused by narcolepsy and idiopathic hypersomnia.